{"id":602434,"date":"2026-07-03T08:27:46","date_gmt":"2026-07-03T08:27:46","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/602434\/overactive-bladder-pipeline-2026-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-medtronic-pfizer-teva-pharma.html"},"modified":"2026-07-03T08:27:46","modified_gmt":"2026-07-03T08:27:46","slug":"overactive-bladder-pipeline-2026-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-medtronic-pfizer-teva-pharma","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/602434\/overactive-bladder-pipeline-2026-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-medtronic-pfizer-teva-pharma.html","title":{"rendered":"Overactive Bladder Pipeline 2026: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Astellas Pharma, Laborie, Hisamitsu Pharma, Medtronic, Pfizer, Teva Pharma"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1783013714.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Overactive Bladder Pipeline 2026: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Astellas Pharma, Laborie, Hisamitsu Pharma, Medtronic, Pfizer, Teva Pharma\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/07\/1783013714.jpg\" alt=\"Overactive Bladder Pipeline 2026: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Astellas Pharma, Laborie, Hisamitsu Pharma, Medtronic, Pfizer, Teva Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic;padding:8px 0px\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/overactive-bladder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Overactive Bladder Pipeline Insight, 2026<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\">The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key takeaways from the Overactive Bladder Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder companies working in the treatment market are <strong>Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others<\/strong>, are developing therapies for the Overactive Bladder treatment<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify\">\n<li>\n<p>Emerging Overactive Bladder therapies in the different phases of clinical trials are-<strong> ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others<\/strong> are expected to have a significant impact on the Overactive Bladder market in the coming years.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Several companies<\/strong> continued to advance investigational therapies for overactive bladder (OAB) aimed at enhancing treatment efficacy, tolerability, and patient adherence, including next-generation &beta;3-adrenergic receptor agonists and innovative neuromodulation-based approaches.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Preliminary findings from the Phase Ib trial (NCT06024642)<\/strong> demonstrated that Sunobinop (V117957), an investigational oral therapy, exhibited encouraging early efficacy and safety in patients with overactive bladder (OAB).<\/p>\n<\/li>\n<li>\n<p><strong>In September 2025, Medtronic<\/strong> has announced that the FDA has approved the Altaviva implantable nerve stimulator for the treatment of urge urinary incontinence (UUI), a frequent symptom associated with overactive bladder (OAB). The device is implanted near the ankle through a minimally invasive procedure and delivers low-level electrical impulses to stimulate the tibial nerve, helping restore communication between the bladder and the brain. Altaviva becomes the third tibial neuromodulation device approved for UUI, following the eCoin device approved in 2022 and the Revi System approved in 2023.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Overview<\/strong><\/p>\n<p style=\"text-align: justify\">Overactive bladder (OAB) is a urinary condition characterized by a frequent and sudden urge to urinate that may be difficult to control. People with OAB often experience urinary urgency, which can lead to involuntary leakage of urine (urge incontinence). This condition can significantly impact daily life and quality of life.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/overactive-bladder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/overactive-bladder-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>ARD-380:<\/strong> Aardvark Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>URB937:<\/strong> Exxel Pharma<\/p>\n<\/li>\n<li>\n<p><strong>Botulax:<\/strong> Hugel<\/p>\n<\/li>\n<li>\n<p><strong>IMB-115:<\/strong> Imbrium Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>TAC-302:<\/strong> Taiho Pharmaceutical<\/p>\n<\/li>\n<li>\n<p><strong>URO-902:<\/strong> Sumitovant Biopharma<\/p>\n<\/li>\n<li>\n<p><strong>DA-8010:<\/strong> Dong-A ST<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\">Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Intra-articular<\/p>\n<\/li>\n<li>\n<p>Intraocular<\/p>\n<\/li>\n<li>\n<p>Intrathecal<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Ophthalmic<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify\">Overactive Bladder Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Oligonucleotide<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Overactive Bladder Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>DelveInsight&#8217;s Overactive Bladder Report covers around 15+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/overactive-bladder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Overactive Bladder therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Some of the key companies in the Overactive Bladder Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify\">Key companies developing therapies for Overactive Bladder are &#8211;<em><strong> Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify\">The Overactive Bladder pipeline report provides insights into<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/overactive-bladder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Overactive Bladder drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Overactive Bladder Pipeline Market Barriers <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of Overactive Bladder Pipeline Drug Insight <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Overactive Bladder Companies:<\/strong> Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Overactive Bladder Therapies:<\/strong> ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others<\/p>\n<\/li>\n<li>\n<p><strong>Overactive Bladder Therapeutic Assessment:<\/strong> Overactive Bladder current marketed and Overactive Bladder emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/overactive-bladder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Overactive Bladder Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Overactive Bladder Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Overactive Bladder Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Overactive Bladder Overview<\/p>\n<p style=\"text-align: justify\">4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify\">5. Overactive Bladder Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify\">6. Overactive Bladder Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify\">7. Overactive Bladder Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify\">8. Overactive Bladder Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify\">9. Overactive Bladder Preclinical Stage Products<\/p>\n<p style=\"text-align: justify\">10. Overactive Bladder Therapeutics Assessment<\/p>\n<p style=\"text-align: justify\">11. Overactive Bladder Inactive Products<\/p>\n<p style=\"text-align: justify\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify\">13. Overactive Bladder Key Companies<\/p>\n<p style=\"text-align: justify\">14. Overactive Bladder Key Products<\/p>\n<p style=\"text-align: justify\">15. Overactive Bladder Unmet Needs<\/p>\n<p style=\"text-align: justify\">16 . Overactive Bladder Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify\">17. Overactive Bladder Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify\">18. Overactive Bladder Analyst Views<\/p>\n<p style=\"text-align: justify\">19. Appendix<\/p>\n<p style=\"text-align: justify\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=overactive-bladder-pipeline-2026-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-medtronic-pfizer-teva-pharma\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679  Source: https:\/\/www.delveinsight.com\/report-store.php<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=overactive-bladder-pipeline-2026-detailed-clinical-trials-and-fdaapproved-therapies-review-by-delveinsight-astellas-pharma-laborie-hisamitsu-pharma-medtronic-pfizer-teva-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/602434"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=602434"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/602434\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=602434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=602434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=602434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}